BMC infectious diseases · 2026
Multidrug-resistant Corynebacterium striatum-induced severe pneumonia complicated with multiple organ failure: a diagnostic breakthrough guided by phagocytosis and therapeutic strategy.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Ruofan, Xu Xiaosong, Zheng Zhilong, Li Ruiying, Cai Xiangsheng
Аннотация
BACKGROUND: Corynebacterium striatum (C. striatum), a Gram-positive opportunistic pathogen, is increasingly linked to healthcare-associated pneumonia (HAP) in immunocompromised patients, but its nonspecific manifestations and multidrug resistance cause diagnostic delays. This case adds to literature by highlighting neutrophil phagocytosis in sputum smears as a pivotal clue for distinguishing C. striatum infection from contamination, especially in mixed infections. A 56-year-old female with uncontrolled diabetes, hypertension, and post-cerebral hemorrhage sequelae developed severe pneumonia, complicated by septic shock, CRRT-requiring acute kidney injury, and gastrointestinal bleeding. Initial therapy for Klebsiella pneumoniae and Pseudomonas aeruginosa failed. Sputum smear showed neutrophils phagocytosing Gram-positive rods; culture confirmed multidrug-resistant C. striatum. Therapy with ceftazidime-avibactam, vancomycin, and caspofungin improved outcomes.
CONCLUSION: Microscopic detection of phagocytosis aids early C. striatum identification; dynamic etiological monitoring and individualized combination therapy are critical for refractory HAP in immunocompromised patients.
CONCLUSION: Microscopic detection of phagocytosis aids early C. striatum identification; dynamic etiological monitoring and individualized combination therapy are critical for refractory HAP in immunocompromised patients.